Table 1.

Tumor progression following administration of docetaxel or TH1902 in ovarian and endometrial cancer xenograft models.

Cancer Indications	Xenograft Models	Groups	Doses (mg/kg)	Tumor Progression a
				Size Increase (x-Fold Day-0)	Significance b (p Values)
Ovarian cancer	ES-2	Vehicle	0	11.84	na
		Docetaxel	3.75	10.08	ns
			15	8.31	ns
		TH1902	8.75	6.70	0.007
			35	2.37	<0.0001
	SKOV3	Vehicle	0	8.63	na
		Docetaxel	3.75	9.70	ns
			15	2.25	0.001
		TH1902	8.75	3.69	0.007
			35	0.94	0.0002
Endometrial cancer	AN3-CA	Vehicle	0	13.27	na
		Docetaxel	3.75	12.07	ns
			15	0.79	<0.0001
		TH1902	8.75	4.59	0.002
			35	0.35	<0.0001

^a Tumor size progression at vehicle group endpoints compared to start of treatments (Day 0). Ratios > 1 indicate tumor progression whereas ratios < 1 indicate tumor regression. ^b Significance between tumor progression of individual group vs. respective vehicle group endpoints using one-way ANOVA with Dunnett’s multiple comparisons test, na: not applicable, ns: not significant.